INSIGHTS ON DRUG DEVELOPMENT

• Lentiviral Vector Upstream Process

  Scalable lentiviral vector production is moving beyond adherent systems. Learn how streamlined workflows enable linear scale-up in stirred-tank bioreactors for cost-effective gene therapy manufacturing.

• Navigating Preclinical Drug Development Challenges With Lipid-Based Formulations

  Maximize the oral bioavailability of challenging small-molecule candidates and streamline the path from preclinical toxicology to clinical trials by leveraging optimized lipid-based formulations.

• CDMOs - Key Collaborators In Streamlining Drug Development

  Accelerating biologics development requires more than speed. Discover how the right CDMO partnership can streamline processes and help you reach the market faster without sacrificing control.

• Navigating Emerging Therapeutics: Cannabinoid And Psilocybin Drug Development

  Cannabinoid and psilocybin therapies are advancing rapidly, and Mikart supports innovators with DEA-licensed facilities, formulation expertise, regulatory guidance, and manufacturing capabilities from clinical development to commercialization.

• Delivering Critical Therapies With Speed And Safety

  6/26/2026

  Faster approvals depend on treating regulation as part of development, not the finish line. See how early quality planning and strong agency communication can move therapies toward patients sooner.

• Ask Us Anything: Erik Feldmann On Advancing Peptide Development

  7/24/2026

  Erik Feldmann, Technical Director, on the analytical challenges of proteins, peptides, and oligonucleotides — and why he starts every method-development problem by understanding what the customer is trying to achieve.

• Take The Wheel And Drive Your Oligo Synthesis Where You Want

  2/9/2026

  Explore the evolving oligo therapeutic landscape while identifying common challenges of bringing production in‑house and the key factors that shape long‑term success for smoother scale‑up.

• Using Residual DNA Quantification Data To De-Risk mAb Development

  6/11/2026

  Residual DNA quantitation offers more than impurity measurement. When used across process steps, it helps compare purification performance, identify risks early, and ensure assays remain reliable.

• Targeted Modalities Set Elevated Standards For Precision

  4/7/2026

  Explore how targeted modalities like ADCs and TPDs are transforming precision medicine, unlocking new treatment opportunities, and overcoming development challenges to improve patient outcomes.